SwePub
Sök i LIBRIS databas

  Extended search

(WFRF:(Öberg Kjell 1946 )) pers:(Caplin Martyn)
 

Search: (WFRF:(Öberg Kjell 1946 )) pers:(Caplin Martyn) > Health-Related Qual...

  • Strosberg, JonathanH Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA (author)

Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With Lu-177-Dotatate in the Phase III NETTER-1 Trial

  • Article/chapterEnglish2018

Publisher, publication year, extent ...

  • AMER SOC CLINICAL ONCOLOGY,2018
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-363624
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-363624URI
  • https://doi.org/10.1200/JCO.2018.78.5865DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • PurposeNeuroendocrine tumor (NET) progression is associated with deterioration in quality of life (QoL). We assessed the impact of Lu-177-Dotatate treatment on time to deterioration in health-related QoL.MethodsThe NETTER-1 trial is an international phase III study in patients with midgut NETs. Patients were randomly assigned to treatment with Lu-177-Dotatate versus high-dose octreotide. European Organisation for Research and Treatment of Cancer quality-of-life questionnaires QLQ C-30 and G.I.NET-21 were assessed during the trial to determine the impact of treatment on health-related QoL. Patients completed the questionnaires at baseline and every 12 weeks until tumor progression. QoL scores were converted to a 100-point scale according to European Organisation for Research and Treatment of Cancer instructions, and individual changes from baseline scores were assessed. Time to QoL deterioration (TTD) was defined as the time from random assignment to the first QoL deterioration 10 points for each patient in the corresponding domain scale. All analyses were conducted on the intention-to-treat population. Patients with no deterioration were censored at the last QoL assessment date.ResultsTTD was significantly longer in the Lu-177-Dotatate arm (n = 117) versus the control arm (n = 114) for the following domains: global health status (hazard ratio [HR], 0.406), physical functioning (HR, 0.518), role functioning (HR, 0.580), fatigue (HR, 0.621), pain (HR, 0.566), diarrhea (HR, 0.473), disease-related worries (HR, 0.572), and body image (HR, 0.425). Differences in median TTD were clinically significant in several domains: 28.8 months versus 6.1 months for global health status, and 25.2 months versus 11.5 months for physical functioning.ConclusionThis analysis from the NETTER-1 phase III study demonstrates that, in addition to improving progression-free survival, Lu-177-Dotatate provides a significant QoL benefit for patients with progressive midgut NETs compared with high-dose octreotide.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Wolin, EdwardMontefiore Einstein Ctr Canc Care, Bronx, NY USA (author)
  • Chasen, BethUniv Texas MD Anderson Canc Ctr, Houston, TX 77030 USA (author)
  • Kulke, MatthewDana Farber Canc Inst, Boston, MA 02115 USA (author)
  • Bushnell, DavidUniv Iowa, Iowa City, IA USA (author)
  • Caplin, MartynRoyal Free Hosp, London, England (author)
  • Baum, Richard P.Zentralklinik, Bad Berka, Germany (author)
  • Kunz, PamelaStanford Univ, Med Ctr, Stanford, CA 94305 USA (author)
  • Hendifar, AndrewCedars Sinai Med Ctr, Los Angeles, CA 90048 USA (author)
  • Hobday, TimothyMayo Clin, Coll Med, Rochester, MN USA (author)
  • Öberg, Kjell,1946-Uppsala universitet,Endokrin tumörbiologi(Swepub:uu)kjellob (author)
  • Sierra, Maribel LoperaAdv Accelerator Applicat, Geneva, Switzerland (author)
  • Thevenet, ThomasAdv Accelerator Applicat, Geneva, Switzerland (author)
  • Margalet, InesAdv Accelerator Applicat, Geneva, Switzerland (author)
  • Ruszniewski, PhilippeParis Diderot Univ, Clichy, France;Hop Beaujon, Clichy, France (author)
  • Krenning, EricErasmus MC, Rotterdam, Netherlands (author)
  • H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USAMontefiore Einstein Ctr Canc Care, Bronx, NY USA (creator_code:org_t)

Related titles

  • In:Journal of Clinical Oncology: AMER SOC CLINICAL ONCOLOGY36:25, s. 2578-25840732-183X1527-7755

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view